[Skip to Navigation]
Sign In
Invited Commentary
Geriatrics
October 21, 2021

Overcoming Therapeutic Inertia in Type 2 Diabetes Care—Timing, Context, and Appropriateness of Treatment Intensification

Author Affiliations
  • 1Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
  • 2Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota
  • 3HealthPartners Institute, Minneapolis, Minnesota
JAMA Netw Open. 2021;4(10):e2130926. doi:10.1001/jamanetworkopen.2021.30926

Timely, evidence-based, and safe control of hyperglycemia is foundational to the management of type 2 diabetes and is essential for preventing acute and chronic complications of this common and serious disease. There are 2 main reasons for suboptimal glycemic control: the patient’s inability, for whatever reason, to adhere to prescribed medication(s) and the clinician’s failure to initiate or intensify glucose-lowering therapy when it is clinically appropriate to do so (ie, therapeutic inertia). Therapeutic inertia is common, affecting as many as 50% of patients with type 2 diabetes,1 and is driven by a wide range of barriers at the clinician, patient, and health system levels.2 Addressing therapeutic inertia is a priority viewed as central to reducing the burden of diabetes and its complications.2

Nearly 30% of adults aged 65 years and older are living with diabetes.3 Glycemic control among older adults is generally better than among younger patients; recent population-based estimates revealed that 24% of older adults without diabetes complications had glycated hemoglobin (HbA1c) levels of 7.5% or greater (ie, the commonly accepted upper threshold for healthier older adults [to convert to proportion of total hemoglobin, multiply by 0.01]), while 20% of older adults with diabetes complications had HbA1c levels of 8.0% or greater3 (ie, the recommended upper threshold for more clinically complex patients), suggesting that there is an opportunity to improve glycemic management and reduce the burden of diabetes complications. Hospitalization may be viewed as an opportunity to address therapeutic inertia and improve glycemic control. However, as demonstrated by Anderson et al4 elsewhere in JAMA Network Open, intensification of glucose-lowering therapy upon hospital discharge does not appear to improve glycemic control but exposes patients to risk of preventable harm due to severe hypoglycemia in the immediate postdischarge period.

As observed by Anderson et al4 in a large retrospective cohort study of patients with non–insulin-treated type 2 diabetes aged 65 years or older who were admitted to US Veterans Health Administration hospitals for a wide range of routine medical problems unrelated to diabetes, having glucose-lowering medications intensified at or before hospital discharge was associated with a 2-fold increase in the rate of severe hypoglycemic events requiring emergency department or hospital care during the initial 30-day period after hospital discharge. There was, however, also a significant reduction in 30-day all-cause mortality (hazard ratio, 0.55; 95% CI, 0.33-0.92), which the authors attribute to unmeasured confounding and lower perceived risk of death among patients who were deemed eligible for treatment intensification. This mortality benefit was limited to patients with preadmission HbA1c levels greater than 7.5% (ie, uncontrolled diabetes) and was no longer apparent after 1 year of follow-up. Indeed, after 1 year, there was no association between glucose-lowering medication intensification and severe hypoglycemic or hyperglycemic events, HbA1c level, all-cause hospitalizations, or mortality.

Depending on one’s perspective, several conclusions can be drawn from this study. On the one hand, treatment intensification at transitions of care appears to be ill advised. Intensification of glucose-lowering medications during hospitalization for causes unrelated to diabetes—the condition whose treatment is being intensified—does not improve glucose control as measured by HbA1c level. Concurrently, it transiently doubles the risk of severe hypoglycemia as patients begin to take their newly prescribed medications, nearly all of which in this study were associated with heightened hypoglycemia risk (ie, insulin and sulfonylurea). On the other hand, treatment intensification may be beneficial, as patients receiving intensified treatment were nearly half as likely to die in that same period. While the finding of decreased short-term mortality in the intensified group may be due to confounding, as the authors suggest, other plausible explanations exist. For example, patients receiving treatment intensification may have closer follow-up in the outpatient setting or derive benefit from improved glycemic control with respect to recovery from illness, infection risk, and wound healing. HbA1c is an imperfect measure of glycemic control given that it overlooks the impacts of real-time glucose levels, glycemic variability, and presence of severe and/or symptomatic hypoglycemia and hyperglycemia, factors that can all lead to morbidity in patients with diabetes.

Another key finding of the study by Anderson and colleagues4 is the poor rate of persistence to newly prescribed medications. Overall, 34.5% of newly prescribed medications were filled only once—at hospital discharge—and never filled again. By 1 year, only 52.0% of patients who had started oral medications and 61.4% of patients who had started insulin were still taking these drugs. This can reflect the fact that prescribed medications were not truly necessary but rather were prescribed for self-limited hyperglycemia or based on assumptions of poor glycemic control stemming from inpatient hyperglycemia and acute illness. These findings further underscore the need for better integration of hospital and ambulatory care, medication reconciliation and review during posthospital follow-up appointments, and comprehensive transitions-of-care programs.

Several factors limit the interpretation of these data. The observational study design precludes causal inference, and a further limitation is the inability to assess the impact of insulin dose adjustments that are likely more prevalent than adding a new type of insulin. Some of the treatment intensifications may not have been clinically appropriate; an earlier study in the same population found that 49% of patients whose treatment regimens were intensified either had limited life expectancy or were already at their individualized HbA1c goal.5 The rate of serious hypoglycemic events is underestimated because it excludes functionally and clinically significant hypoglycemia that did not lead to emergency department or inpatient treatment. Medication intensification is defined as the introduction of a new class of medication or an increase in the dose of an existing noninsulin medication, which would misclassify substitution of 1 glucose-lowering medication for another as an intensification. Finally, few study subjects were receiving sodium-glucose transport protein 2 (SGLT2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist medications either before or after their index hospitalizations, which occurred from 2011 to 2016; nearly all patients were started on insulin or sulfonylureas.

However, the world has changed a lot since 2016. Emerging evidence and current diabetes clinical guidelines advise that many patients with type 2 diabetes and established cardiovascular or kidney disease may benefit from adjusting medication regimens to include SGLT2 inhibitor and/or GLP-1 receptor agonist medications, which did not occur in this study. Initiation of these medication classes in patients such as those in this study, of whom more than half had coronary artery disease and kidney disease and more than one-third had heart failure, may well have resulted in lower rates of hypoglycemia, hospitalizations, and deaths.

In this context, a new set of research questions emerges. First, which patients are appropriate candidates for safe and effective treatment intensification, and with which medications? SGLT2 inhibitors and GLP-1 receptor agonists should be considered for patients with high risk of cardiovascular disease, but what about patients with moderate levels of risk? Second, what is the optimal timing and clinical context for treatment intensification when such action is clinically appropriate? Third, how can we best inform patients of the benefits and risks of alternative care options to effectively engage in shared decision-making that may improve medication adherence? Fourth, better coordination of care between inpatient and outpatient settings deserves our attention. Addressing therapeutic inertia and making care transitions safer require ongoing innovation and testing a wide variety of potential improvement strategies, ranging from improvement in health informatics systems to the use of social workers or nurses to facilitate communication and coordination of care around the time of hospital discharge. These efforts are commendable, but ultimately their success depends on a proactive, resilient primary care system that is well integrated with hospital care.6

Back to top
Article Information

Published: October 21, 2021. doi:10.1001/jamanetworkopen.2021.30926

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 McCoy RG et al. JAMA Network Open.

Corresponding Author: Rozalina G. McCoy, MD, MS, Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (mccoy.rozalina@mayo.edu).

Conflict of Interest Disclosures: Dr McCoy reported receiving grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the AARP, and the Patient-Centered Outcomes Research Institute outside the submitted work. Dr O’Connor reported receiving support from the Patient-Centered Outcomes Research Institute; the Agency for Healthcare Research and Quality; the National Heart, Lung, and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Mental Health; the National Institute on Drug Abuse; and the National Cancer Institute.

References
1.
Rattelman  CR, Ciemins  EL, Stempniewicz  N, Mocarski  M, Ganguly  R, Cuddeback  JK.  A retrospective analysis of therapeutic inertia in type 2 diabetes management across a diverse population of health care organizations in the USA.   Diabetes Ther. 2021;12(2):581-594. doi:10.1007/s13300-020-00993-wPubMedGoogle ScholarCrossref
2.
Gabbay  RA, Kendall  D, Beebe  C,  et al.  Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association.   Clin Diabetes. 2020;38(4):371-381. doi:10.2337/cd20-0053PubMedGoogle ScholarCrossref
3.
Wang  L, Li  X, Wang  Z,  et al.  Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018.   JAMA. 2021;326(8):1-13. doi:10.1001/jama.2021.9883PubMedGoogle ScholarCrossref
4.
Anderson  TS, Lee  AK, Jing  B,  et al.  Intensification of diabetes medications at hospital discharge and clinical outcomes in older adults in the Veterans Administration health system.   JAMA Netw Open. 2021;4(10):e2128998. doi:10.1001/jamanetworkopen.2021.28998Google Scholar
5.
Anderson  TS, Jing  B, Auerbach  A,  et al.  Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge.   JAMA Intern Med. 2019;179(11):1528-1536. doi:10.1001/jamainternmed.2019.3007PubMedGoogle ScholarCrossref
6.
Grumbach  K, Bodenheimer  T, Cohen  D, Phillips  RL, Stange  KC, Westfall  JM.  Revitalizing the U.S. primary care infrastructure.   N Engl J Med. 2021. doi:10.1056/NEJMp2109700PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×